摘要：

In patients without cirrhosis, the diagnosis of hepatocellular carcinoma (HCC) requires a biopsy and is routinely done by a pathologist with an expertise in liver pathology. Navigating complex treatment algorithms for patients with HCC requires that patients are presented and discussed at an interdisciplinary tumor board. Several studies have shown that response to locoregional therapies for HCCs while waiting on the transplantation list correlates to post‐transplant cancer recurrence and long‐term outcome, and may be used as a surrogate to tumor biology in outcome predictions. In patients with underlying liver disease and cirrhosis, de novo HCC remains a long‐term risk. Recurrences within 3 years of a curative approach are usually considered a recurrence, while those that occur after 3 years are more consistent with de novo HCC. Different types of cell‐based therapies are being tested for the treatment of patients with HCC.

展开